The Results of the IBIS II Trial
Charles L. Shapiro, MD, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.
Charles L. Shapiro, MD, professor, College of Medicine, The James, Ohio State University Comprehensive Care Center, discusses the IBIS II trial, which studied anastrozole in preventing breast cancer in postmenopausal women at increased risk of breast cancer.
Clinical Pearls:
- IBIS II is a prevention study in over 3,000 women who were randomized to anastrozole vs placebo
- Anastrozole proved to be 50% effective in presenting breast cancer, primarily ER+ breast cancer, compared to the placebo
- There was only a 10% difference in the grades of musculoskeletal arthralgias when comparing anastrozole to the placebo
Sequencing Sacituzumab and Other Drugs in HR+, HER2- Breast Cancer
May 16th 2024During a Case-Based Roundtable® event, Stephanie L. Graff, MD, discussed multiple later-line treatment options in hormone receptor–positive breast cancer with participants in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Darolutamide Becomes Routine Doublet and Triplet Option in Hormone-Sensitive Prostate Cancer
May 6th 2024Darolutamide has been adopted routinely in clinical practice as a component of both doublet and triplet regimens for the treatment of patients with metastatic hormone-sensitive prostate cancer.
Read More
